MCM
SGNT

Matarin Capital Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Matarin Capital Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,799
Closed -$251K – 213
2015
Q1 		$251K Buy
+10,799
New +$286K 0.08% 177

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Matarin Capital Management's SGNT Position: Q2 2015 in Review

Matarin Capital Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2015, closing a stake of 10,799 shares — an estimated $251K sold.

Matarin Capital Management first reported a position in SGNT in Q1 2015 and held it in 1 quarter. The position peaked at $251K in Q1 2015. 136 funds tracked by Wall St. Rank hold SGNT as of Q2 2015.

  • Matarin Capital Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Matarin Capital Management sold 10,799 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $251K.
  • Matarin Capital Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q1 2015 and held it in 1 quarter.
  • Matarin Capital Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $251K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on Matarin Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.